MedTrace Logo

Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan

NCT01777061 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2018-05-16

No results posted yet for this study

Summary

When evaluating prostate cancer patients for recurrent disease, computed tomography (CT), and magnetic resonance imaging (MRI) are both highly sensitive methods for detecting lymph nodes, but are not specific as to whether the lymph nodes are malignant or benign.

While positron emission tomography (PET) utilizing radioactive glucose (FDG) has revolutionized staging, restaging, and monitoring response to therapy in many prevalent cancers such as breast, colorectal, esophageal, head and neck, lung, lymphoma, and melanoma, findings with prostate cancer have proven less sensitive because prostate cancer has a lower avidity for glucose. A newer PET isotope, utilizing acetate that is incorporated into the cell membrane of rapidly proliferating cells, has shown greater sensitivity than FDG in detecting prostate cancer.

This study will assess the clinical effectiveness of utilizing \[11C\]Acetate PET scans in identifying recurrent prostate cancer.

Conditions

Interventions

DRUG

[11C]Acetate

intravenous injection of an average of 40 mCi of \[11C\]Acetate

Sponsors & Collaborators

  • University of Kansas Medical Center

    collaborator OTHER

  • Wendell Yap, MD

    lead OTHER

Principal Investigators

  • Wendell Yap, MD · University of Kansas Medical Center

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777061 on ClinicalTrials.gov